(0.34%) 5 117.35 points
(0.34%) 38 370 points
(0.39%) 15 990 points
(-0.94%) $83.06
(5.36%) $2.03
(0.34%) $2 355.20
(0.54%) $27.68
(4.10%) $959.90
(-0.28%) $0.932
(-0.46%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer...
Stats | |
---|---|
本日の出来高 | 137 621 |
平均出来高 | 928 424 |
時価総額 | 107.34M |
EPS | $0 ( 2024-03-11 ) |
次の収益日 | ( $-0.0400 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -158.50 |
ATR14 | $0.00300 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Mccarthy Sean A. | Buy | 109 768 | Common Stock |
2024-03-26 | Mccarthy Sean A. | Sell | 109 768 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 76 000 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 0 | |
2024-03-19 | Rowland Lloyd A | Sell | 5 268 | Common Stock |
INSIDER POWER |
---|
64.84 |
Last 98 transactions |
Buy: 4 891 928 | Sell: 1 103 909 |
ボリューム 相関
CytomX Therapeutics Inc 相関
10 最も正の相関 | |
---|---|
GURE | 0.925 |
EYEG | 0.922 |
DIBS | 0.919 |
SWVL | 0.918 |
EIGR | 0.917 |
JOAN | 0.917 |
AFIB | 0.916 |
LPSN | 0.913 |
QRTEA | 0.912 |
RUBY | 0.911 |
10 最も負の相関 | |
---|---|
SGEN | -0.906 |
GETVV | -0.903 |
STAY | -0.894 |
PUCKU | -0.887 |
TVTY | -0.886 |
CCRC | -0.886 |
DSPG | -0.884 |
ALTR | -0.875 |
SNCR | -0.875 |
MTEK | -0.873 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
CytomX Therapeutics Inc 相関 - 通貨/商品
CytomX Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $101.21M |
総利益: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2023 |
収益: | $101.21M |
総利益: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2022 |
収益: | $53.16M |
総利益: | $47.31M (88.98 %) |
EPS: | $-1.480 |
FY | 2021 |
収益: | $69.57M |
総利益: | $69.57M (100.00 %) |
EPS: | $-1.300 |
Financial Reports:
No articles found.
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。